Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -25.37 Million SEK | -20.07% |
| 2022 | -21.13 Million SEK | -16.77% |
| 2021 | -18.09 Million SEK | -45.09% |
| 2020 | -12.47 Million SEK | -15.93% |
| 2019 | -10.75 Million SEK | 12.23% |
| 2018 | -12.25 Million SEK | -76.68% |
| 2017 | -6.93 Million SEK | -122.66% |
| 2016 | -3.11 Million SEK | -101.66% |
| 2015 | -1.54 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.64 Million SEK | 64.12% |
| 2024 Q2 | -4.64 Million SEK | 0.0% |
| 2023 Q2 | -12.43 Million SEK | -100.0% |
| 2023 Q4 | -12.94 Million SEK | -100.0% |
| 2023 FY | -25.37 Million SEK | -20.07% |
| 2023 Q3 | -6.47 Million SEK | 47.96% |
| 2023 Q1 | -6.21 Million SEK | 41.54% |
| 2022 Q2 | -10.5 Million SEK | -100.0% |
| 2022 Q4 | -10.63 Million SEK | -100.0% |
| 2022 Q3 | -5.31 Million SEK | 49.36% |
| 2022 Q1 | -5.25 Million SEK | 42.52% |
| 2022 FY | -21.13 Million SEK | -16.77% |
| 2021 Q1 | -4.43 Million SEK | 39.22% |
| 2021 Q2 | -8.87 Million SEK | -100.0% |
| 2021 Q3 | -4.56 Million SEK | 48.53% |
| 2021 Q4 | -9.13 Million SEK | -100.0% |
| 2021 FY | -18.09 Million SEK | -45.09% |
| 2020 Q4 | -7.29 Million SEK | -100.0% |
| 2020 Q2 | -5.08 Million SEK | -100.01% |
| 2020 Q3 | -3.64 Million SEK | 28.22% |
| 2020 FY | -12.47 Million SEK | -15.93% |
| 2020 Q1 | -2.54 Million SEK | 58.78% |
| 2019 Q3 | -3.08 Million SEK | 31.31% |
| 2019 FY | -10.75 Million SEK | 12.23% |
| 2019 Q4 | -6.16 Million SEK | -100.01% |
| 2019 Q2 | -4.48 Million SEK | -100.01% |
| 2019 Q1 | -2.24 Million SEK | 0.0% |
| 2018 FY | -12.25 Million SEK | -76.68% |
| 2017 FY | -6.93 Million SEK | -122.66% |
| 2016 FY | -3.11 Million SEK | -101.66% |
| 2015 FY | -1.54 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 67.4% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 124.517% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 124.517% |
| Arcoma AB | 2.56 Million SEK | 1089.67% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 81.663% |
| BICO Group AB (publ) | -835.7 Million SEK | 96.964% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 201.594% |
| CellaVision AB (publ) | 130.3 Million SEK | 119.473% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 68.198% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 13.059% |
| C-Rad AB (publ) | 35.52 Million SEK | 171.421% |
| Duearity AB (publ) | -26.19 Million SEK | 3.111% |
| Dignitana AB (publ) | -17.36 Million SEK | -46.145% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 73.233% |
| Getinge AB (publ) | 2.41 Billion SEK | 101.052% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 62.671% |
| Iconovo AB (publ) | -45.89 Million SEK | 44.709% |
| Integrum AB (publ) | 4.03 Million SEK | 729.269% |
| Mentice AB (publ) | -2.81 Million SEK | -800.786% |
| OssDsign AB (publ) | -130.49 Million SEK | 80.554% |
| Paxman AB (publ) | 8.33 Million SEK | 404.623% |
| Promimic AB (publ) | -9.22 Million SEK | -175.159% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 84.136% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 54.349% |
| ScandiDos AB (publ) | -14.64 Million SEK | -73.245% |
| Sectra AB (publ) | 428.38 Million SEK | 105.923% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 57.433% |
| Senzime AB (publ) | -134.14 Million SEK | 81.084% |
| SpectraCure AB (publ) | -20.44 Million SEK | -24.138% |
| Stille AB | 26.64 Million SEK | 195.231% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.341% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 127.636% |